Skip to main content

Table 3 Relationships between changes in the Fib-4 index in the pemafibrate group and changes in metabolic parameters over the 52-week study period

From: Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage

 

ΔFib-4 index

 

Variables

ρ

P value

ΔBMI

0.014

0.865

ΔTriglyceride

0.098

0.229

ΔHDL-C

0.018

0.817

ΔLDL-C

−0.185

0.023

ΔRLP-C

0.079

0.347

ΔApoA1

0.051

0.548

ΔApoB

−0.075

0.377

ΔApoE

0.113

0.179

ΔLDL-C/apoB

−0.204

0.015

Δγ-GTP

0.060

0.459

ΔeGFR

−0.019

0.815

ΔHbA1c

−0.063

0.443

  1. P-values were obtained by Spearman’s rank correlation analysis. BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RLP-C, remnant-like particle cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; ApoE, apolipoprotein E; γ-GTP, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; Hb1c, glycated hemoglobin
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us